Develops ready-made cancer immunotherapies targeting tumor mutations for patients with pancreatic, colorectal and other cancers.
10-K for FY2025, filed Mar 12, 2026We are a clinical-stage biotechnology company advancing novel immunotherapies for the treatment of cancer, including mutant Kirsten rat…View ↗
Our lead programs focus on our cancer immunotherapy product candidates, which target biologically validated driver tumor mutations using…View ↗
Our clinical pipeline includes the lymph node targeted cancer immunotherapy ELI-002 7P, currently being evaluated in a Phase 2 study…View ↗
10-Q for Q3 FY2026, filed Nov 5, 2026
−$8MView ↗
From fibrosis drugs to cancer immunotherapies
The older report describes a small-molecule drug pipeline for fibrotic and other diseases; the latest report centers on ready-made immunotherapies targeting tumor mutations in cancers.
10-K for FY2022, filed Mar 17, 2023 10-K for FY2025, filed Mar 12, 2026OverviewView ↗
Competes with Amgen, Mirati Therapeutics, AstraZeneca, BioNTech, BridgeBio Oncology Therapeutics, Boehringer Ingelheim, Bristol Myers Squibb, Circio, D3 Bio, Eli Lilly, Erasca, Geneos, Gilead Sciences, Incyte, Jacobio Pharma, Jiangsu Hengrui Pharmaceuticals, Merck, Moderna, Roche, and Revolution Medicines
10-K for FY2025, filed Mar 12, 2026In addition to the current standard of care treatments for patients, numerous commercial and academic preclinical studies and clinical…View ↗
Loading...